Si-Tu Xue

567 total citations
30 papers, 432 citations indexed

About

Si-Tu Xue is a scholar working on Molecular Biology, Oncology and Epidemiology. According to data from OpenAlex, Si-Tu Xue has authored 30 papers receiving a total of 432 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 13 papers in Oncology and 6 papers in Epidemiology. Recurrent topics in Si-Tu Xue's work include Bone Metabolism and Diseases (7 papers), Bone health and treatments (5 papers) and FOXO transcription factor regulation (4 papers). Si-Tu Xue is often cited by papers focused on Bone Metabolism and Diseases (7 papers), Bone health and treatments (5 papers) and FOXO transcription factor regulation (4 papers). Si-Tu Xue collaborates with scholars based in China. Si-Tu Xue's co-authors include Zhuorong Li, Hong Yi, Zong‐Ying Liu, Jian‐Dong Jiang, Xingyue Ji, Huifang Guo, Jiajia Shen, Yuhuan Li, Yang Gao and Rong‐Mei Gao and has published in prestigious journals such as Nature Communications, Cell Metabolism and International Journal of Molecular Sciences.

In The Last Decade

Si-Tu Xue

30 papers receiving 425 citations

Peers

Countries citing papers authored by Si-Tu Xue

Since Specialization

Citations

This map shows the geographic impact of Si-Tu Xue's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Si-Tu Xue with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Si-Tu Xue more than expected).

Fields of papers citing papers by Si-Tu Xue

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Si-Tu Xue. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Si-Tu Xue. The network helps show where Si-Tu Xue may publish in the future.

Co-authorship network of co-authors of Si-Tu Xue

This figure shows the co-authorship network connecting the top 25 collaborators of Si-Tu Xue. A scholar is included among the top collaborators of Si-Tu Xue based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Si-Tu Xue. Si-Tu Xue is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Cathepsin D promotes acute myeloid leukemia progression through stabilization of the anti-apoptotic proteins 2025 ·Cell Death and Disease ·Huimin Jiang, Yong‐Jian Wang, (unknown), (unknown), Shujuan Wang, Feng Wang, Si-Tu Xue, (unknown), Haigen Fu, Ting Dong, Jian Yuan, Zhuorong Li, Ke Li	1
2	A Novel Class of Multi‐substituted Diaryl Scaffold Derivatives Inhibit Glioblastoma Progression by Targeting CD155 2025 ·Advanced Science ·Yong‐Jian Wang, (unknown), Si-Tu Xue, (unknown), Yi Hong, (unknown), (unknown), Rui Liu, Peng Xu, Zhuorong Li	1
3	BMP2–ERK–ATF4 Axis-Based 6-methoxybenzofuran Compound I-9 Acts as Candidate Drug for Bone Formation and Anti-Osteoporosis 2024 ·International Journal of Molecular Sciences ·(unknown), Chenxi Zhao, Siyan Li, (unknown), (unknown), Si-Tu Xue, Zhuorong Li	3
4	Osteoporosis: Emerging targets on the classical signaling pathways of bone formation 2024 ·European Journal of Pharmacology ·(unknown), Si-Tu Xue, Zhuorong Li	6
5	Adipocyte-derived glutathione promotes obesity-related breast cancer by regulating the SCARB2-ARF1-mTORC1 complex 2024 ·Cell Metabolism ·Chenxi Zhao, Tingting Zhang, Si-Tu Xue, Peitao Zhang, (unknown), Yunxuan Li, Ying Liu, (unknown), Jie Wu, (unknown), Xiaoyun Mao, Yuping Chen, Jian Yuan, Zhuorong Li, Ke Li	11
6	Substituted indole derivatives as UNC-51-like kinase 1 inhibitors: Design, synthesis and anti-hepatocellular carcinoma activity 2024 ·Biomedicine & Pharmacotherapy ·Luyao Zhao, (unknown), (unknown), (unknown), Ke Li, Si-Tu Xue, Jian‐Dong Jiang	2
7	Design and synthesis of dabigatran etexilate derivatives with inhibiting thrombin activity for hepatocellular carcinoma treatment 2023 ·Biomedicine & Pharmacotherapy ·(unknown), (unknown), (unknown), (unknown), (unknown), Lei Zhang, Si-Tu Xue	1
8	SCARB2 drives hepatocellular carcinoma tumor initiating cells via enhanced MYC transcriptional activity 2023 ·Nature Communications ·Feng Wang, Yang Gao, Si-Tu Xue, (unknown), (unknown), Tingting Zhang, Yunxuan Li, Chenxi Zhao, Fan Wu, (unknown), Ying Liu, Jie Wu, Yechao Yan, Jian Yuan, Jian‐Dong Jiang, Ke Li	15
9	Small molecule targeting FOXM1 DNA binding domain exhibits anti-tumor activity in ovarian cancer 2022 ·Cell Death Discovery ·(unknown), Si-Tu Xue, (unknown), (unknown), (unknown), Jing Wang, Zhuorong Li, Zhaojian Liu	21
10	Synthesis and antineoplastic activity of ethylene glycol phenyl aminoethyl ether derivatives as FOXM1 inhibitors 2022 ·European Journal of Medicinal Chemistry ·(unknown), Jing Geng, (unknown), (unknown), (unknown), Yi Hong, (unknown), Si-Tu Xue, Zhuorong Li	1
11	Structure-based virtual screening identified novel FOXM1 inhibitors as the lead compounds for ovarian cancer 2022 ·Frontiers in Chemistry ·(unknown), (unknown), (unknown), (unknown), Si-Tu Xue, Zhuorong Li	4
12	<p>Synthesis and Bioactivity of <em>N</em>-(4-Chlorophenyl)-4-Methoxy-3-(Methylamino) Benzamide as a Potential Anti-HBV Agent</p> 2020 ·Drug Design Development and Therapy ·(unknown), Wenfang Sun, (unknown), Jie Jin, Si-Tu Xue, Shuo Wu, Yuhuan Li, Zhuorong Li	4
13	Substituted benzothiophene and benzofuran derivatives as a novel class of bone morphogenetic Protein-2 upregulators: Synthesis, anti-osteoporosis efficacies in ovariectomized rats and a zebrafish model, and ADME properties 2020 ·European Journal of Medicinal Chemistry ·Si-Tu Xue, Lei Zhang, (unknown), Jie Jin, Huifang Guo, Hong Yi, Zong‐Ying Liu, Zhuorong Li	8
14	7-Pyrrolidinethoxy-4′-Methoxyisoflavone Prevents Amyloid β–Induced Injury by Regulating Histamine H3 Receptor-Mediated cAMP/CREB and AKT/GSK3β Pathways 2019 ·Frontiers in Neuroscience ·Linlin Wang, Jiansong Fang, Hailun Jiang, Qian Wang, Si-Tu Xue, Zhuorong Li, Rui Liu	9
15	Synthesis and biological evaluation of novel synthetic chalcone derivatives as anti-tumor agents targeting Cat L and Cat K 2017 ·Bioorganic & Medicinal Chemistry ·Yali Wang, Si-Tu Xue, Ruolan Li, Zhihui Zheng, Hong Yi, Zhuorong Li	23
16	Design, synthesis and biological evaluation of novel benzimidazole-2-substituted phenyl or pyridine propyl ketene derivatives as antitumour agents 2016 ·European Journal of Medicinal Chemistry ·(unknown), Zhi‐Hong Jiang, Jiajia Shen, Hong Yi, (unknown), (unknown), Zhen Wang, Si-Tu Xue, Zhuorong Li	44
17	Synthesis of a novel class of substituted benzothiophene or benzofuran derivatives as BMP-2 up-regulators and evaluation of the BMP-2-up-regulating effects in vitro and the effects on glucocorticoid-induced osteoporosis in rats 2015 ·European Journal of Medicinal Chemistry ·Si-Tu Xue, Huifang Guo, Meijie Liu, Jie Jin, Dahong Ju, Zong‐Ying Liu, Zhuorong Li	20
18	Design, synthesis and antiproliferative activity of a novel class of indole-2-carboxylate derivatives 2014 ·European Journal of Medicinal Chemistry ·Xingyue Ji, Si-Tu Xue, (unknown), Jiajia Shen, (unknown), Jie Jin, Zhen Wang, Zhuorong Li	15
19	Design, synthesis and in vitro and in vivo antitumour activity of 3-benzylideneindolin-2-one derivatives, a novel class of small-molecule inhibitors of the MDM2–p53 interaction 2014 ·European Journal of Medicinal Chemistry ·Guanghui Zheng, Jiajia Shen, (unknown), Yi Hong, Si-Tu Xue, Zhen Wang, Xingyue Ji, Zhuorong Li	29
20	Synthesis and antiviral activity of some novel indole-2-carboxylate derivatives 2014 ·Acta Pharmaceutica Sinica B ·Si-Tu Xue, Linlin Ma, Rong‐Mei Gao, Yuhuan Li, Zhuorong Li	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact